TY - JOUR
T1 - Alvimopan for the management of postoperative ileus after bowel resection
T2 - Characterization of clinical benefit by pooled responder analysis
AU - Ludwig, Kirk
AU - Viscusi, Eugene R.
AU - Wolff, Bruce G.
AU - Delaney, Conor P.
AU - Senagore, Anthony
AU - Techner, Lee
PY - 2010/9
Y1 - 2010/9
N2 - Background: A pooled post hoc responder analysis was performed to assess the clinical benefit of alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist, for the management of postoperative ileus after bowel resection. Methods: Adult patients who underwent laparotomy for bowel resection scheduled for opioid-based intravenous patient-controlled analgesia received oral alvimopan or placebo preoperatively and twice daily postoperatively until hospital discharge or for 7 postoperative days. The proportion of responders and numbers needed to treat (NNT) were examined on postoperative days (POD) 3-8 for GI-2 recovery (first bowel movement, toleration of solid food) and hospital discharge order (DCO) written. Results: Alvimopan significantly increased the proportion of patients with GI-2 recovery and DCO written by each POD (P < 0.001 for all). More patients who received alvimopan achieved GI-2 recovery on or before POD 5 (alvimopan, 80%; placebo, 66%) and DCO written before POD 7 (alvimopan, 87%; placebo, 72%), with corresponding NNTs equal to 7. Conclusions: On each POD analyzed, alvimopan significantly increased the proportion of patients who achieved GI-2 recovery and DCO written versus placebo and was associated with relatively low NNTs. The results of these analyses provide additional characterization and support for the overall clinical benefit of alvimopan in patients undergoing bowel resection.
AB - Background: A pooled post hoc responder analysis was performed to assess the clinical benefit of alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist, for the management of postoperative ileus after bowel resection. Methods: Adult patients who underwent laparotomy for bowel resection scheduled for opioid-based intravenous patient-controlled analgesia received oral alvimopan or placebo preoperatively and twice daily postoperatively until hospital discharge or for 7 postoperative days. The proportion of responders and numbers needed to treat (NNT) were examined on postoperative days (POD) 3-8 for GI-2 recovery (first bowel movement, toleration of solid food) and hospital discharge order (DCO) written. Results: Alvimopan significantly increased the proportion of patients with GI-2 recovery and DCO written by each POD (P < 0.001 for all). More patients who received alvimopan achieved GI-2 recovery on or before POD 5 (alvimopan, 80%; placebo, 66%) and DCO written before POD 7 (alvimopan, 87%; placebo, 72%), with corresponding NNTs equal to 7. Conclusions: On each POD analyzed, alvimopan significantly increased the proportion of patients who achieved GI-2 recovery and DCO written versus placebo and was associated with relatively low NNTs. The results of these analyses provide additional characterization and support for the overall clinical benefit of alvimopan in patients undergoing bowel resection.
UR - http://www.scopus.com/inward/record.url?scp=79952113772&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952113772&partnerID=8YFLogxK
U2 - 10.1007/s00268-010-0635-9
DO - 10.1007/s00268-010-0635-9
M3 - Article
C2 - 20526599
AN - SCOPUS:79952113772
SN - 0364-2313
VL - 34
SP - 2185
EP - 2190
JO - Presentations from the 9th Annual Electric Utilities Environmental Conference
JF - Presentations from the 9th Annual Electric Utilities Environmental Conference
IS - 9
ER -